Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › Medicare Covers Adaptive Biotechnologies' ClonoSeq Assay

Medicare Covers Adaptive Biotechnologies' ClonoSeq Assay

Jan 18, 2019
|
staff reporter

NEW YORK (GenomeWeb) – Adaptive Biotechnologies said after the close of the market on Thursday that Medicare contractor Palmetto GBA has established coverage of its next-generation sequencing-based assay, ClonoSeq, for Medicare patients with multiple myeloma and B-cell acute lymphoblastic leukemia.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Feb
23
Featured Webinar

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

Feb
24
Featured Webinar

Case Study: Rapid Development and Manufacturing Scaleup of a Point-of-Care COVID-19 Test

Sponsored by
SCHOTT MINIFAB

Developing a fully integrated consumable cartridge for an automated diagnostic platform is a significant challenge. More challenging still is developing such a cartridge in response to a deadly global virus pandemic amid market uncertainty and extraordinary time constraints. 

What's Popular?

In Sequencing

  1. Invitae, Pharma Firms Partner to Develop Standard MRD Panel for AML Clinical Trials

  2. Illumina CEO Discusses Pan-Cancer IVD Assay, CDx Collaborations at JP Morgan

  3. Pacific Biosciences, Invitae to Develop Clinical Whole-Genome Sequencing Platform

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.